Savara Inc Research and Development Asset Acquired Other than Through Business Combination, Written-off
Savara Inc (SVRA) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $995.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2020-03-12
- Savara Inc research and development asset acquired other than through business combination, written-off for fiscal 2018 was $995.00K.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|
| 2018-12-31 | $995.00K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |